Home > Insider Trading > Filing (0001062993-23-006867)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1177648	Enanta Pharmaceuticals Inc	ENTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1571211	R. Jay Luly	C/O Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown MA 02472	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-03-13	27,912	$14.00	847,722	No	4	M	Direct
Common Stock	Disposition	2023-03-13	10,697	$44.81	837,025	No	4	S	Direct
Common Stock	Disposition	2023-03-13	15,649	$45.31	821,376	No	4	S	Direct
Common Stock	Disposition	2023-03-13	1,566	$46.13	819,810	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-03-13	27,912	$0.00	27,912	$14.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2023-03-21	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.39 to $44.99, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.54, inclusive.
On March 21, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, half of which became exercisable upon the achievement of several clinical milestones during the four-year performance period after the date of grant.